Middle East Business: Kuwait’s KSPICO signs pact with Rosemont Pharmaceuticals – Gulf Digital News

Middle East Business: Kuwait’s KSPICO signs pact with Rosemont Pharmaceuticals – Gulf Digital News

Kuwait’s only manufacturer of pharmaceutical products, Kuwait Saudi Pharmaceutical Industries Company (KSPICO), announced today (December 6) the signing of a “License and Supply” strategic partnership agreement with Rosemont Pharmaceuticals.

The partnership enables KSPICO to bolster its capabilities and offerings in the healthcare space and reinforce its position in the GCC and Middle East and North Africa (Mena’s) growing pharma markets, a statement said.

The agreement was signed at the British Embassy in Kuwait by Rosemont Pharmaceuticals’ Head of International Sales, Mark Vallance and KSPICO’s Chairman and Managing Director Dr Rashed Khazal. Through this partnership, KSPICO will distribute a range of 'Rosemont' products in the GCC and Mena regions, including oral liquid formulations ranges and oral liquid medicines to support both pediatric and geriatric patients with swallowing difficulties.

The British Ambassador to the State of Kuwait, Her Excellency Belinda Lewis, commented: “I am delighted to see the start of a collaboration between Rosemont Pharmaceuticals and KSPICO (Kuwait Saudi Pharmaceutical Industries Co.), a leading Kuwaiti pharmaceutical manufacturer. The UK is a global leader in life sciences and innovative biopharmaceuticals. Our pharmaceutical industry is at the forefront of developing lifesaving medicines as well as making them more accessible around the world. The UK’s biopharma market contributes